Thursday, November 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document

Untitled source document

No live link available for this source.

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Zacks Rank #1 equal-weight portfolio outperformed the equal-weight S&P 500 index by 7.7 percentage points year-to-date 2026 through March 3, 2026, returning +6.57% versus the S&P 500's -1.14%.

    60% confidence
  • Over the 10-year period from 2016 through 2025, the equal-weight Zacks Rank #1 portfolio outperformed the equal-weight S&P 500 index by more than 7 percentage points, returning +18.55% versus +11.65%.

    60% confidence
  • In 2025, the Zacks Rank #1 equal-weight portfolio returned +17.81% versus +10.85% for the equal-weight S&P 500 index.

    60% confidence
  • In 2024, the Zacks Rank #1 equal-weight portfolio returned +22.4% versus +13.7% for the equal-weight S&P 500 index.

    60% confidence
  • Retail sales increased 1.7% in March, fueled by a 15.5% spike in gas station receipts, indicating resilient consumer demand.

    60% confidence
  • Empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements, which is the core of the Zacks Rank system.

    60% confidence
  • The market remains highly sensitive to geopolitical developments and policy uncertainties despite domestic data suggesting a sturdy economic floor.

    60% confidence
  • Yara International shares have gained 24.1% since the Zacks Rank #1 upgrade on Feb 18, compared to the S&P 500's 4.6% increase.

    60% confidence
  • BGC Group has returned 22.4% since its Zacks Rank #2 upgrade on February 17, compared to the S&P 500's 4.8% increase.

    60% confidence
  • Consumer sentiment for April hit a record low of 47.6, reflecting deep anxiety over the Iran conflict and a 4.8% jump in inflation expectations.

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com